[go: up one dir, main page]

CL2008001124A1 - Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. - Google Patents

Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.

Info

Publication number
CL2008001124A1
CL2008001124A1 CL2008001124A CL2008001124A CL2008001124A1 CL 2008001124 A1 CL2008001124 A1 CL 2008001124A1 CL 2008001124 A CL2008001124 A CL 2008001124A CL 2008001124 A CL2008001124 A CL 2008001124A CL 2008001124 A1 CL2008001124 A1 CL 2008001124A1
Authority
CL
Chile
Prior art keywords
cancer
useful
treatment
acid derivative
pharmaceutical formulation
Prior art date
Application number
CL2008001124A
Other languages
English (en)
Inventor
Robert G L Shorr
Robert J Rodriguez
Rajinder Bhasin
Original Assignee
Cornerstone Phamraceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornerstone Phamraceuticals Inc filed Critical Cornerstone Phamraceuticals Inc
Publication of CL2008001124A1 publication Critical patent/CL2008001124A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación farmacéutica que comprende al menos un derivado de ácido lipoico y un reactivo formador de par iónico, útil en el tratamiento del cáncer.
CL2008001124A 2007-04-18 2008-04-18 Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. CL2008001124A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91260507P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
CL2008001124A1 true CL2008001124A1 (es) 2009-01-02

Family

ID=39872894

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001124A CL2008001124A1 (es) 2007-04-18 2008-04-18 Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.

Country Status (19)

Country Link
US (4) US20080262077A1 (es)
EP (1) EP2144609B1 (es)
JP (1) JP5480804B2 (es)
KR (1) KR101539785B1 (es)
CN (1) CN101820875B (es)
AR (1) AR067309A1 (es)
AU (1) AU2008242827B2 (es)
BR (1) BRPI0810439B1 (es)
CA (1) CA2684479C (es)
CL (1) CL2008001124A1 (es)
ES (1) ES2528414T3 (es)
IL (1) IL201581A (es)
MX (1) MX2009011165A (es)
NZ (1) NZ580973A (es)
PL (1) PL2144609T3 (es)
PT (1) PT2144609E (es)
SA (1) SA08290240B1 (es)
TW (1) TWI459944B (es)
WO (1) WO2008131114A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체
MX2009011165A (es) 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh
CN102056605A (zh) * 2008-04-04 2011-05-11 罗伯特·绍尔 药物组合物
CA2745383A1 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
CA2782676C (en) 2009-12-01 2021-06-15 Shire Human Genetic Therapies, Inc. Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CN102657606B (zh) * 2012-05-25 2014-01-01 江苏神龙药业有限公司 一种供静脉给药用的硫辛酸注射液
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
US20150322103A1 (en) * 2012-12-19 2015-11-12 Cornerstone Pharmaceuticals, Inc. Pharmaceutical compounds
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
MX365409B (es) 2013-03-14 2019-05-31 Shire Human Genetic Therapies Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados.
CN103360437B (zh) * 2013-04-27 2015-10-21 江苏教育学院 一种硫辛酸糖类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN103497344B (zh) * 2013-09-25 2015-09-23 深圳先进技术研究院 用于负载贵金属颗粒的纳米凝胶及其制备方法与应用
EP3060303B1 (en) 2013-10-22 2018-11-14 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
KR20250005450A (ko) 2014-04-25 2025-01-09 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
WO2015195070A1 (en) * 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
AU2014398233B2 (en) * 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
TW202114651A (zh) * 2019-08-16 2021-04-16 美商拉斐爾製藥公司 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
US20230092232A1 (en) * 2020-02-28 2023-03-23 University Of Florida Research Foundation, Incorporated Compounds that modulate anti-tumor immunity and methods of doing the same
JP2023549086A (ja) * 2020-11-03 2023-11-22 コーナーストーン ファーマシューティカルズ，インコーポレーテッド デビミスタットを使用して胆道癌を治療するための治療法及び組成物
CN119770650A (zh) * 2025-01-09 2025-04-08 华中科技大学 一种硫辛酸-胆碱离子液体溶液及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805251A (en) * 1953-07-22 1957-09-03 Ethyl Corp Preparation of aryloxyaliphatic acids and salts thereof
GB758897A (en) 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US3002011A (en) * 1953-12-04 1961-09-26 Merck & Co Inc Intermediates and processes for producing alpha-lipoic acid
US2809978A (en) * 1953-12-04 1957-10-15 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2980716A (en) * 1954-06-11 1961-04-18 Research Corp Method for preparing 6, 8-dihalooctanoic esters
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2852531A (en) * 1954-09-24 1958-09-16 Merck & Co Inc Tris-(2-tetrahydropyranyl) esters of 6, 8-bis (hydrocarbonmercapto)-4, 4-dicarboxy-5-ocaprylic acid and preparation thereof
US2875238A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2875239A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2985685A (en) * 1959-01-26 1961-05-23 American Cyanamid Co Alkanolamine aluminates as catalysts for ester redistribution
US3453312A (en) * 1966-04-27 1969-07-01 Merck & Co Inc (beta - (substituted-thio) - acylphenoxy)-alkanoic acids and (beta-(substitutedthio) acylphenylmercapto) alkanoic acids and derivatives thereof
US3345368A (en) * 1967-02-15 1967-10-03 American Cyanamid Co Substituted 7-acetylamino cephalosporanic acids
US3881017A (en) * 1973-05-18 1975-04-29 Ciba Geigy Corp 9-Thiaprostaglandin compositions
DE2422498A1 (de) * 1973-05-18 1974-12-05 Ciba Geigy Ag Neue thiaprostaglandine und verfahren zu ihrer herstellung
JPS5323539Y2 (es) * 1973-11-30 1978-06-17
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
US5344941A (en) * 1986-09-03 1994-09-06 Samour Carlos M Water soluble salts of thionaphthene-2-carboxylic acid
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
EP1486495B1 (en) * 1998-10-26 2009-12-09 The Research Foundation of State University of New York Salts of lipoic acid derivatives and their use in treatment of disease
US7320797B2 (en) * 2003-08-29 2008-01-22 Bioderm Research Antiaging cosmetic delivery systems
JP2007077066A (ja) * 2005-09-14 2007-03-29 Shiseido Co Ltd 不全角化抑制剤、毛穴縮小剤
US20090036356A1 (en) * 2006-03-06 2009-02-05 Avestha Gengraine Technologies Pvt. Ltd. Octanoic acid derivatives as dipeptidyl peptidase inhibitors
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
MX2009011165A (es) 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체

Also Published As

Publication number Publication date
AU2008242827A1 (en) 2008-10-30
EP2144609B1 (en) 2014-10-29
EP2144609A4 (en) 2010-06-16
US8691873B2 (en) 2014-04-08
EP2144609A2 (en) 2010-01-20
AR067309A1 (es) 2009-10-07
CN101820875A (zh) 2010-09-01
KR20100029744A (ko) 2010-03-17
WO2008131114A3 (en) 2010-01-21
MX2009011165A (es) 2009-12-09
BRPI0810439B1 (pt) 2021-06-29
IL201581A (en) 2016-04-21
PT2144609E (pt) 2015-02-06
BRPI0810439A2 (pt) 2014-10-07
US20120178812A1 (en) 2012-07-12
HK1140424A1 (en) 2010-10-15
JP2010524963A (ja) 2010-07-22
TW200901964A (en) 2009-01-16
WO2008131114A2 (en) 2008-10-30
US20080262077A1 (en) 2008-10-23
IL201581A0 (en) 2010-05-31
US20170056355A1 (en) 2017-03-02
US9320726B2 (en) 2016-04-26
PL2144609T3 (pl) 2015-04-30
SA08290240B1 (ar) 2012-02-22
CA2684479A1 (en) 2008-10-30
KR101539785B1 (ko) 2015-07-27
AU2008242827B2 (en) 2014-06-05
US9872845B2 (en) 2018-01-23
ES2528414T3 (es) 2015-02-10
CN101820875B (zh) 2014-07-23
CA2684479C (en) 2017-11-14
US20150011633A1 (en) 2015-01-08
TWI459944B (zh) 2014-11-11
NZ580973A (en) 2011-10-28
JP5480804B2 (ja) 2014-04-23

Similar Documents

Publication Publication Date Title
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
CR20120202A (es) Métodos y composiciones para tratar cáncer
CL2015000829A1 (es) Inhibidores de histona desmetilasas
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
ECSP10010216A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
BR112016005252A2 (pt) composto direcionado às proteínas poliposi coli adematosa (apc) truncadas, uso do mesmo e célula epitelial do cólon humana imortalizada (hcec)
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica